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Erectile dysfunction (ED) is generally defined as the persistent (at least 
6 months) inability to achieve and maintain penile erection sufficient 
to allow satisfactory sexual performance.1 It is a common condition, 
and recent studies predict a higher prevalence of ED in the future.2 It is 
estimated that ED has affected more than 150 million men worldwide 
and this number will reach approximately 322 million by 2025.2,3 It has 
affected 30 million men in the US alone.4 
Ischaemic heart disease (IHD), also known as coronary artery disease 
(CAD), is a predominant manifestation of cardiovascular disease (CVD). 
CVD is the leading cause of morbidity and mortality, accounting for 
17.3 million deaths globally every year; this figure is expected to 
grow to 23.6 million by the year 2030. Eighty per cent of these deaths 
occur in lower- and middle-income countries.5 ED and IHD are highly 
prevalent and occur concomitantly because they share the same 
risk factors, including diabetes, hypertension, hyperlipidaemia, obesity 
and smoking. 
The incidence of ED is 42.0–57.0  % in men with CAD and 33.8  % in 
those who have diabetes with silent ischaemia, compared with 4.7 % 
in men without silent ischaemia.6 The prevalence of ED is likely to be 
higher than the reported figures, because men generally do not seek 
medical advice for ED.6 Erection is thought to be a process that is 
regulated by hormones and neurovascular mechanisms in cerebral 
and peripheral levels.7 
Causes of ED may be of primary developmental origin or secondary. 
Lack of sex hormone in the early developmental stage of male 
children is the major cause of primary ED. The secondary cause of ED 
involves arteriosclerosis, diabetes or psychogenic disturbances. Other 
secondary factors may include hypertension, hyperlipidaemia, obesity 
and tobacco use. The primary causes of ED are beyond the scope of 
this review; we will not be discussing the neurovascular mechanisms 
pertaining to ED and will focus on the relationship between IHD and ED.
Association Between ED and IHD
The association of ED and IHD has been a constant matter of study. 
Many previous studies have documented that IHD and ED are linked. 
IHD can be used to predict the risk of ED because both conditions have 
the same risk factors. Conversely, ED may trigger events that further 
lead to IHD. 
ED is generally associated with significant changes in established 
cardiovascular risk factors. Atherosclerosis is the main cause of ED 
development in both the general population and patients with diabetes. 
However, the prevalence of ED is greater in patients with diabetes than 
in the general population.8 ED has been shown to occur at rates as high 
as 50 % in patients with CAD.9 A meta-analysis of 12 prospective cohort 
studies has provided evidence that ED is a predictor of IHD associated 
with an increased risk of CVD, stroke and all-cause mortality.10
Previous studies reported that there is a strong chance of future 
cardiac events when ED occurs in younger men compared with older 
men.11 Another study suggested that there is consistent association 
across age groups.12 A study of men with diabetes found that ED 
acts as an indicator of cardiovascular events after adjusting for other 
illnesses, psychological aspects and the usual cardiovascular risk 
factors.13 Another large-scale study comprising 25,650 men with pre-
existing ED suggested that these men had a 75  % increased risk of 
peripheral vascular disease.14 Moreover, some studies demonstrated 
a relationship between ED score and number of diseased coronary 
arteries and plaque burden in coronary arteries.2,15
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A study that examined the association between ED and asymptomatic 
CAD showed that 67  % of patients had ED for a mean 38.8 months 
before developing symptoms of CAD.16 Interestingly, all patients with 
type 1 diabetes in this study had ED well before symptoms of CAD.
Artery size also explains the onset of ED before occurrence of CAD. 
Coronary arteries are 3–4 mm in diameter, while the penile artery 
is 1–2 mm in diameter.17 Endothelial dysfunction and plaque burden 
in the small arteries may cause symptoms of ED before they affect 
blood flow in large arteries. Also, an asymptomatic lipid-rich plaque 
in the coronary arteries carries the risk of rupture that leads to acute 
coronary syndrome or death, so ED may be predictive of these serious 
events without warning cardiac symptoms.17
Some commonly prescribed cardiovascular drugs (beta-blockers, 
diuretics, angiotensin-converting enzyme inhibitors, etc.) contribute 
to ED.18 Previous studies have shown a strong association between 
ED and diuretics in patients treated with hydrochlorothiazide or 
chlorthalidone.19,20 It has also been shown that patients treated with 
first-generation non-selective beta-blockers, such as propranolol, had 
more frequent ED than those treated with a placebo.21 
Second-generation cardioselective beta-blockers (atenolol, metoprolol, 
bisoprolol, etc.) can also lead to ED. Atenolol was shown to cause 
significant reduction of sexual activity compared with placebo in 
a double-blind, parallel-arm study.22 The same study also showed 
a significant reduction in testosterone levels with atenolol versus 
valsartan. An open, prospective study of hypertensive men treated 
with atenolol, metoprolol and bisoprolol for at least 6 months showed 
high prevalence of ED – approaching 66 % – in these patients.23
The impact of third-generation cardioselective beta-blockers such 
as carvedilol and nebivolol has also been investigated. Fogari et 
al. investigated the effect of carvedilol on erectile function in a 
double-blind crossover study involving 160 men newly diagnosed 
with hypertension and found chronic worsening of sexual function in 
those treated with carvedilol compared with valsartan and placebo.24 
Nebivolol seems to have an advantage over other beta-blockers 
when used to treat men with hypertension and ED. It has additional 
vasodilating effects because it stimulates endothelial release of 
nitric oxide (NO), resulting in relaxation of smooth muscle in the 
corpus cavernosum, allowing penile erection.25 Despite limited 
studies, nebivolol does not seem to worsen erectile function 
and some studies have demonstrated significant improvement in 
erectile function with nebivolol compared with second-generation 
cardioselective beta-blockers.23,26–28 
Most studies into the effect of beta-blockers on ED point to negative 
effects of first- and second-generation beta-blockers, while beta-
blockers with vasodilating effects can improve erectile function. 
Alpha-blockers, calcium channel blockers, and angiotensin-converting 
enzyme inhibitors seem to have a neutral effect on erectile function. 
Multiple previous studies have demonstrated a beneficial effect of 
angiotensin receptor blockers on erectile function and they should 
probably be the favoured antihypertensive agents in patients with ED.29
Aetiology
In most men, ED is recognised as sharing vascular aetiology with 
IHD.17 ED and IHD share common risk factors, such as hypertension, 
hyperlipidaemia, diabetes, obesity, lack of physical exercise, cigarette 
smoking, poor diet, excess alcohol consumption and psychological 
stress, including depression.30 Endothelial dysfunction has been 
implicated as a common mechanism between CAD and ED and it has 
an important role in the development of atherosclerosis.31 
The role of endothelial dysfunction in CAD is well known.32,33 Also, 
endothelial-derived NO induces vasodilatation, which in turn is an 
important event to achieve normal erectile function.34–36 Moreover, 
systemic endothelial-dependent vasodilatation has been shown to be 
reduced in men with ED.37,38
Risk Factors
ED and IHD share the same risk factors (Figure 1). Endothelial 
dysfunction is the common link between ED and IHD.5
Age
Age is a critical risk factor for the development of ED and endothelial 
dysfunction.4,5 ED is the most common condition occurring in 
middle-aged and older men.5 Kinsey et al. reported that 25  % of 
65-year-old men and 75 % of ≥80-year-old men have ED.39 Moreover, 
ageing also decreases endothelial function, which is responsible 
for IHD.5 The incidence and severity of ED increases with age (a 
man aged 70 years is three-times more likely to have ED than 
a man aged 40 years).40
Blood Pressure
Hypertension can affect endothelial function in many ways. 
It can reduce endothelium-dependent vasodilatation by increasing 
the vasoconstrictor tone as a result of increased peripheral 
sympathetic activity.41–43 Another mechanism is hypertension-induced 
increase in cyclooxygenase activity that leads to an increase in 
reactive oxygen species; these in turn damage endothelial cells and 
disrupt their function.44–46 In some cases, endothelial NO synthase 
(eNOS) gene variations may relate to hypertension-associated 
endothelial dysfunction.6
Cholesterol
High cholesterol level is an independent risk factor for ED. A 22-month 
follow-up study estimated that each mmol/l increase in baseline total 
cholesterol level increases the risk of ED by 1.32 times.4 In a study by 
Seftel et al., 42 % of men with ED also had hyperlipidaemia.47 In another 
study, 114 patients with ED had elevated LDL cholesterol.48
Figure 1: Risk Factors Associated with Erectile 
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Smoking
Smoking is an independent risk factor for ED. Tobacco smoking causes 
direct toxicity to endothelial cells, including decreased eNOS activity, 
increased adhesion expression and impaired regulation of thrombotic 
factors.6 A meta-analysis of 19 studies by Tengs and Osgood suggested 
that 40  % of the impotent men studied were current smokers 
compared with 28 % who had never smoked.49
Obesity
Obesity is a strong predictor of ED as it is associated with other risk 
factors, such as diabetes, hyperlipidaemia and hypertension.4 Obesity 
increases the risk of ED by 30–90  % and acts as an independent 
risk factor for CVD. Obese men with ED have greater impairment in 
endothelial function than non-obese men with ED.5 Moreover, high BMI 
causes low testosterone levels, which in turn leads to ED, as observed 
in a prospective trial involving 7,446 participants.50 
Psychological
A considerable number of patients with ED can have psychogenic 
factors as the only cause, or in combination with organic causes of 
ED. Depression, low self-esteem and social stresses are among the 
psychogenic factors that can lead to ED. Depression is an independent 
risk factor for both ED and IHD; these three disease conditions 
are interlinked.51 Psychogenic ED can be managed by multiple 
psychological interventions such as cognitive behavioural therapy, 
couples counselling and guided sexual stimulation techniques.52
Diabetes
ED is a common complication of diabetes and people with diabetes are 
also prone to developing cardiovascular complications.48 The risk of ED 
is relatively high in patients with known CVD. This was supported by a 
study of men with known CVD, in which ED was substantially predictive 
of all-cause mortality and the composite of CVD death, admission for 
heart failure, MI and stroke.17 Macroangiopathy, microangiopathy and 
endothelial dysfunction are among the mechanisms by which diabetes 
causes ED.
Subnormal testosterone levels have also been observed in patients with 
diabetes and this is thought to be either autoimmune or a result of low 
levels of sex hormone binding globulin secondary to insulin resistance.53
Pathophysiology of Erectile Dysfunction and 
Ischaemic Heart Disease
Normal penile erection is controlled by two mechanisms: reflex 
erection and psychogenic erection. Reflex erection occurs by directly 
touching the shaft of the penis, while psychogenic erection occurs by 
erotic or emotional stimuli. ED is a condition where erection does not 
take place by either mechanism. ED can occur because of hormonal 
imbalance, neural disorders or lack of adequate blood supply to the 
penis.54 Lack of blood supply can be a result of impaired endothelial 
function associated with CAD.54
The vascular endothelium has an important role in angiogenesis and 
vascular repair by producing regulatory substances, including NO, 
prostaglandin, endothelins, prostacyclin and angiotensin II. These 
regulatory factors regulate the blood flow to the penis by controlling 
smooth muscle contractility and subsequent vasoconstriction and 
vasodilatation. Generally, in erectile tissue, increased blood flow 
through the cavernosal artery increases shear stress and produces 
NO, which further relaxes the vascular smooth muscles and increases 
blood flow in the corpora cavernosa.54 These events cause penile 
erection. However, in ED, endothelial NO synthesis is reduced and there 
is increased endothelial cell death (Figure 2).55
Myocardial ischaemia is caused by the reduction of coronary blood 
flow as a result of fixed or dynamic epicardial coronary artery 
stenosis, abnormal constriction or deficient relaxation of coronary 
microcirculation, or because of reduced oxygen-carrying capacity of 
the blood.56 Atherosclerosis is the major cause of myocardial ischaemia. 
Plaque that develops in atherosclerosis can rupture causing platelet 
aggregation and subsequent thrombus formation, which leads to MI. 
The other mechanisms of myocardial ischaemia are encountered far 
less than atherosclerosis. Endothelial dysfunction has an important role 
in the progression of atherosclerosis. Endothelial dysfunction enhances 
the intimal proliferation and malregulation that results in plaque 
destabilisation in the arteries.6 This process, coupled with paradoxical 
vasoconstriction, can result in major cardiovascular events such as MI.32
Treatment of Erectile Dysfunction in Men with 
Ischaemic Heart Disease
The third Princeton Consensus (Expert Panel) Conference recommends 
assessing cardiovascular risk in all patients with ED and CVD. This 
refers to estimating the risk of mortality and morbidity associated 
with sexual activity. The current recommendations classify patients 
into low-, intermediate- and high-risk, based on their New York Heart 
Association class.57 The consensus also recommended that all patients 
with ED and CVD should undergo lifestyle changes, such as exercise, 
smoking cessation, healthy diet and weight reduction. These measures 
are likely to reduce cardiovascular risk and improve erectile function.58 
Patients with ED at high risk of cardiovascular events should refrain 
from sexual activity until they are stable from a cardiovascular point 
of view. Their management should be under close supervision from 
a cardiologist.58 
PDE5 Inhibitors 
Guidelines recommend that phosphodiesterase type 5 (PDE5) 
inhibitors are the first-line drug for the treatment of ED (Table 1). 
Sildenafil citrate was the first oral drug approved for ED in the US.59 
The newer PDE5 inhibitors include vardenafil, tadalafil and avanafil. 
The inhibition of PDE5 enhances cyclic guanosine monophosphate 
(cGMP)-NO-mediated vasodilatation by preventing PDE5 catabolism 
of cGMP and so delaying detumescence. PDE5 inhibitors increase 
the number and duration of erections, as well as the percentage of 
successful sexual intercourse.60
Figure 2: Pathophysiology of Erectile Dysfunction and 
Ischaemic Heart Disease
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PDE5 inhibitors are commonly prescribed to treat ED. The second 
Princeton Consensus Conference reviewed their appropriate use 
and recent studies of placebo-controlled and post-marketing 
surveillance data have confirmed their safety regarding 
cardiovascular events.61–63 
Olsson et al. conducted a randomised, double-blind, placebo-
controlled, parallel group, and flexible dose study in 224 men with 
ED and one CVD, including IHD (20  %) and hypertension (80  %). 
This study reported that the sildenafil-treated group showed 71  % 
improvement in ED compared with the placebo-controlled group 
(24  %).64 Furthermore, no treatment-related cardiovascular adverse 
events were reported.65 Conti et al. showed in an early study that 
sildenafil is an effective treatment for ED in patients with IHD; the 
majority of patients reported improvement in penile erection with it.66 
Another double-blind, placebo-controlled study of patients with ED and 
stable CAD showed statistically significant improvement with sildenafil 
versus placebo in both the frequency of penetration and frequency of 
maintained erections after penetration.67
However, sildenafil should be used carefully with nitrates because 
their combination can result in severe hypotension and death.68 
Both short- and long-acting nitrates are commonly prescribed 
to treat angina, but they have no prognostic benefit. In addition, 
there are numerous alternatives to treat angina, such as ranolazine 
and ivabradine, which do not interact with PDE5 inhibitors. As a 
result, patients with ED wishing to take PDE5 inhibitors can safely 
discontinue their nitrates and replace this treatment with the other 
anti-anginal agents.68 
The safety of PDE5 inhibitors in patients with IHD has been shown in 
multiple trials. Arruda-Olson et al. investigated the safety of sildenafil 
during exercise stress tests in patients with IHD to ascertain whether 
the drug induces or exacerbates myocardial ischaemia. This was a 
prospective, randomised crossover study that demonstrated safety 
of sildenafil when given 1 hour before an exercise stress test.69 
Another study that investigated 120 trials of sildenafil revealed that 
the rates of MI and cardiovascular death with sildenafil are as low as 
with placebo.70 
The recommended dosage of sildenafil is 50 mg/day, usually taken 
1 hour before sexual activity. This dose may be increased to 100 mg or 
decreased to 25 mg based on side-effects.6 PDE5 inhibitors also have a 
beneficial effect in the treatment of heart failure with reduced ejection 
fraction as well as pre- and post-capillary pulmonary hypertension. The 
use of PDE5 inhibitors in the treatment of right heart failure and left 
ventricular failure associated with combined pre- and post-capillary 
pulmonary hypertension has been well studied.71,72
Vacuum Devices 
Vacuum erection devices are an effective first-line treatment for ED, 
regardless of the underlying cause. They can be used in combination 
with PDE5 inhibitors and they have high reported satisfaction rates. 
They are generally well tolerated, with minor adverse effects such as 
bruising, pain and failure to ejaculate.73 
Testosterone 
It is recommended that testosterone be measured in patients with 
ED because low levels are a reliable measure of hypogonadism. 
Hypogonadism is not only a treatable cause of ED, but can also lead 
to reduced or lack of response to PDE5 inhibitors.73 Testosterone 
deficiency is also associated with increased cardiovascular and all-
cause mortality.74 Levels >350 ng/dl do not usually require replacement, 
but in patients with testosterone <230 ng/dl, replacement can usually 
be beneficial.57 In patients with congestive heart failure, testosterone 
replacement can lead to fluid retention, so caution is advised. In these 
patients, the aim should be to keep testosterone levels in the middle 
range, i.e. 350–600 ng/dl.57 
Testosterone cypionate and testosterone enanthate injections 
are used for replacement therapy in patients with low testosterone. 
Other formulations, such as gels and patches, are recommended 
in older patients with chronic conditions.57 Serum prostate 
specific antigen should be measured before starting testosterone 
replacement, then 3–6 months after starting the treatment, followed by 
annual measurement.74
The benefits of testosterone replacement and the potential 
cardiovascular risks need to be thoroughly investigated, ideally 
through randomised controlled trials. 
Other Therapies
Intracavernosal and intraurethral injections are second-line therapy 
for patients with ED. Alprostadil is the agent most commonly used for 
intracavernosal injections. The main adverse effects of intracavernosal 
injections are painful erection, priapism and development of scarring 
at the injection site.73 Alprostadil is also available as a topical cream in 
patients who cannot tolerate injections.75 
Another injection option is the combination of phentolamine and 
aviptadil. This is effective, but requires simultaneous sexual stimulation 
to achieve its desired effect.73 Side-effects include headache, facial 
flushing and, rarely, tachycardia and palpitation.73
Intraurethral prostaglandin E1 pellets are suppositories that 
are inserted into the urethra. These agents act by relaxation of 
cavernous smooth muscle, which elevates the intracavernosal cGMP 
and by blocking the local alpha-receptors, resulting in improved 
erectile function.2 
Another second-line treatment is low intensity extracorporeal 
shockwave therapy. This can be very useful, especially in patients who 
failed oral therapy, but do not wish to start injections.73 
Penile prosthesis is recommended as third-line treatment for patients 
who are fit for surgery and intolerant of oral medication, injections or 
external device therapy. A penile prosthesis is particularly useful in 
patients with severe organic ED, achieving long-term effects and high 
satisfaction rates without the need for further medication.73 
Table 1: Treatment Options for Erectile Dysfunction
Therapy Stage Treatment Options
First line 1. Phosphodiesterase type 5 inhibitors
2. Vacuum erection devices
Second line 1. Intracavernosal and intraurethral injections
2. Topical creams
3.  Low-intensity extracorporeal shockwave 
therapy
Third line Penile prosthesis
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Future Treatment Options
Gene therapy has the potential to become a future management option 
for patients with CAD and ED. Animal studies have been conducted 
to evaluate the effects of gene therapy. A rat model was studied by 
Bivalacqua et al. to evaluate the effect of the combination of eNOS gene 
therapy and sildenafil. This research suggested that erectile response 
was greater in male rats with diabetes treated with combination eNOS 
gene therapy and sildenafil, compared with male rats with diabetes 
treated with eNOS gene therapy or sildenafil alone.76–78 
Stem cell therapy is an attractive treatment modality and an appealing 
option for tissue regenerative therapy for ED. Stem cells are pluripotent 
cells that can be produced from multiple regions within the body. They 
have the potential to divide and differentiate into numerous kinds 
of human cells, such as endothelial cells and smooth muscle.79 The 
efficacy and safety of gene and stem cell therapy in patients with ED 
and IHD need to be extensively investigated because both seem to 
have the potential to correct underlying abnormalities in ED. This would 
be a huge development in terms of management options for patients 
with ED and IHD.
Conclusion
ED is a common disease affecting men with IHD. Endothelial dysfunction 
is the link between ED and IHD and both diseases share the same 
aetiology, risk factors and pathogenesis. Aggressive control of these 
risk factors – along with lifestyle modification – is recommended to 
improve symptoms of ED and reduce cardiovascular risk. PDE5 inhibitors 
remain the first-choice treatment for ED in IHD patients and they 
have been shown to be safe and effective. However, PDE5 inhibitors 
can potentiate the hypotensive effect of nitrates so concomitant 
administration of sildenafil and nitrates is contraindicated. Gene and stem 
cell therapy are being investigated as a future therapies for ED. 
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